CLYM · Climb Bio, Inc.
$12.11
-0.18 (-1.46%)
At close · Jul 29
Market Cap
$703.73M
Shares
57.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.11
Open$12.42
Day$11.93–12.58
52W$1.36–14.42
Avg vol 30d1.4M
Short int6.9M · 12.0% float · 5.1d
Short vol64%
Last earningsMay 7, 2026
DataAug 2021–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Sep 18, 2026
Est · unconfirmed
· in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+74%
above
Price vs 50-day avg
+0%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
82%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+140%
trailing
YTD return
+203%
this year
Relative strength
+132%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Distributing
9 of 80 funds reported for Jun 30 · net -86.6K sh shares · +6 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.00% of float · ▲ +34.8% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
80 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
EPS growth
+42%
Y/Y
Free cash flow
$-54.5M
Balance sheet
$35.7M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+74%
Bullish
Price vs 50-day avg
+0%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $7 — 50d above 200d
Institutional flow
Distributing
9 of 80 funds reported for Jun 30 · net -86.6K sh shares · +6 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.00% of float · ▲ +34.8% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
80 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $12 · 82%
52-wk high $14
vs 200-day avg +74%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLYM
this stock
Climb Bio, Inc.
|
$703.73M | +202.8% | — | — | 12.0% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLYM | -3.7% | -7.1% | +139.8% | -7.1% | +202.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.8% | -7.1% | +132.4% | -6.3% | +194.1% |
Key facts
CIK
1768446
CUSIP
28658R106
13F (30d)
10 filings
10 filers
Visit website
Investor relations